Mersana Therapeutics (MRSN)
(Real Time Quote from BATS)
$3.23 USD
+0.07 (2.22%)
Updated Apr 30, 2024 03:16 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Mersana Therapeutics, Inc. [MRSN]
Reports for Purchase
Showing records 81 - 100 ( 197 total )
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Float Like a Butterfly and STING Like an ADC
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SITC 2020 Abstract Preview for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Financials; New STING Mechanism? And an Eventful End to 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Consistent Efficacy in Interim Update at ESMO
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Update; Durability of Response in Focus with Full Program Review Expected During 4Q20
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Eagerly Awaiting CDD Phase 3 Readout in 3Q; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Financials; Updated XMT-1536 Ovarian Cancer Data Ahead at ESMO
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Horses for Courses; A Preclinical Overview of the NaPi2b Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D